{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T07:10:27Z","timestamp":1761030627232,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.cardfail.2021.11.010","type":"journal-article","created":{"date-parts":[[2021,11,14]],"date-time":"2021-11-14T00:17:23Z","timestamp":1636849043000},"page":"554-563","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0885-1953","authenticated-orcid":false,"given":"Muthiah","family":"Vaduganathan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Chiswell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam D.","family":"Devore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna C.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Kittleson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen E.","family":"Joynt Maddox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James J.","family":"Mcdermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjali Tiku","family":"Owens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela N.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orly","family":"Vardeny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clyde W.","family":"Yancy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregg C.","family":"Fonarow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"21","key":"10.1016\/j.cardfail.2021.11.010_bib0001","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cardfail.2021.11.010_bib0002","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.cardfail.2021.11.010_bib0003","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.cardfail.2021.11.010_bib0004","first-page":"531","article-title":"CCS\/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction","volume":"37","author":"McDonald","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0005","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","author":"McDonagh","year":"2021","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.cardfail.2021.11.010_bib0006","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","article-title":"2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversig","volume":"77","author":"Maddox","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.cardfail.2021.11.010_bib0007","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jchf.2019.12.015","article-title":"Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry","volume":"8","author":"Vaduganathan","year":"2020","journal-title":"JACC Heart Fail"},{"issue":"7","key":"10.1016\/j.cardfail.2021.11.010_bib0008","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/ejhf.2163","article-title":"Virtual optimization of guideline-directed medical therapy in hospitalized patients with heart failure with reduced ejection fraction: the IMPLEMENT-HF pilot study","volume":"23","author":"Bhatt","year":"2021","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0009","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/01.hpc.0000243588.00012.79","article-title":"Overview of the American Heart Association \u201cGet with the guidelines\u201d programs: Coronary heart disease, stroke, and heart failure","volume":"5","author":"Hong","year":"2006","journal-title":"Critical Pathways in Cardiology"},{"issue":"4","key":"10.1016\/j.cardfail.2021.11.010_bib0010","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1177\/1536867X1801700402","article-title":"Reconstructing time-to-event data from published kaplan-meier curves","volume":"17","author":"Wei","year":"2017","journal-title":"Stata J"},{"year":"2003","series-title":"Modelling Survival Data in Medical Research","author":"Collett","key":"10.1016\/j.cardfail.2021.11.010_bib0011"},{"issue":"8","key":"10.1016\/j.cardfail.2021.11.010_bib0012","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jamacardio.2020.7472","article-title":"National Trends in Heart Failure Hospitalizations and Readmissions from 2010 to 2017","volume":"6","author":"Agarwal","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"12","key":"10.1016\/j.cardfail.2021.11.010_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004873","article-title":"National Burden of Heart Failure Events in the United States, 2006 to 2014","volume":"11","author":"Jackson","year":"2018","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.cardfail.2021.11.010_bib0014","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jamacardio.2020.5864","article-title":"Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice: The Get with the Guidelines-Heart Failure (GWTG-HF) Registry","volume":"6","author":"Vaduganathan","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0015","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamacardio.2021.0496","article-title":"Simultaneous or Rapid Sequence Initiation of Quadruple Medical Therapy for Heart Failure - Optimizing Therapy with the Need for Speed","volume":"6","author":"Greene","year":"2021","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0016","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","article-title":"Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial","volume":"143","author":"Packer","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.cardfail.2021.11.010_bib0017","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jamacardio.2020.7585","article-title":"Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients with Heart Failure with Reduced Ejection Fraction","volume":"6","author":"Berg","year":"2021","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.cardfail.2021.11.010_bib0018","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1016\/j.cardfail.2021.11.010_bib0019","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1093\/eurheartj\/ehaa183","article-title":"Effects of dapagliflozin in DAPA-HF according to background heart failure therapy","volume":"41","author":"Docherty","year":"2020","journal-title":"Eur Heart J"},{"issue":"11","key":"10.1016\/j.cardfail.2021.11.010_bib0020","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jacc.2021.01.044","article-title":"Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced","volume":"77","author":"Ferreira","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"10.1016\/j.cardfail.2021.11.010_bib0021","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jchf.2020.11.009","article-title":"Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0022","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients with Heart Failure with Reduced Ejection Fraction: Results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0023","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and Kidney Benefits of Empagliflozin in Heart Failure across the Spectrum of Kidney Function: Insights from EMPEROR-Reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0024","article-title":"Cost-effectiveness of dapagliflozin in chronic heart failure: an analysis from the Australian healthcare perspective","author":"Savira","year":"2020","journal-title":"Eur J Prev Cardiol"},{"issue":"6","key":"10.1016\/j.cardfail.2021.11.010_bib0025","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1002\/ehf2.12844","article-title":"Cost-effectiveness of adding dapagliflozin to standard treatment for heart failure with reduced ejection fraction patients in China","volume":"7","author":"Yao","year":"2020","journal-title":"ESC Hear Fail"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0026","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijcard.2020.08.017","article-title":"Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction","volume":"322","author":"Krittayaphong","year":"2021","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.cardfail.2021.11.010_bib0027","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1002\/ejhf.1978","article-title":"Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF","volume":"22","author":"McEwan","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"10.1016\/j.cardfail.2021.11.010_bib0028","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/jamacardio.2021.1437","article-title":"Cost-effectiveness of Dapagliflozin for Treatment of Patients with Heart Failure with Reduced Ejection Fraction","volume":"6","author":"Parizo","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2021.11.010_bib0029","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCULATIONAHA.119.044133","article-title":"Efficacy and Safety of Dapagliflozin in Heart Failure with Reduced Ejection Fraction According to Age: Insights from DAPA-HF","volume":"141","author":"Martinez","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.cardfail.2021.11.010_bib0030","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"10.1016\/j.cardfail.2021.11.010_bib0031","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/ejhf.2135","article-title":"Prevention of heart failure events with sodium\u2013glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk","volume":"23","author":"Bhatia","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"10254","key":"10.1016\/j.cardfail.2021.11.010_bib0032","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0140-6736(20)31824-9","article-title":"SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials","volume":"396","author":"Zannad","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cardfail.2021.11.010_bib0033","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ejhf.2075","article-title":"SOLOIST-WHF and updated meta-analysis: sodium\u2013glucose co-transporter 2 inhibitors should be initiated in patients hospitalized with worsening heart failure","volume":"23","author":"Docherty","year":"2021","journal-title":"Eur J Heart Fail"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642100470X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107191642100470X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:47:14Z","timestamp":1761029234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107191642100470X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S107191642100470X"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2021.11.010","relation":{},"ISSN":["1071-9164"],"issn-type":[{"type":"print","value":"1071-9164"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Projected Clinical Benefits of Implementation of SGLT-2 Inhibitors Among Medicare Beneficiaries Hospitalized for Heart Failure","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2021.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}